证券日报网讯12月29日，优宁维（301166）在互动平台回答投资者提问时表示，长三角地区作为我国最 具活力的经济发展区域之一，公司总部位于长三角的中心城市上海，并在南京、杭州、合肥等地设有子 公司和办事处；为更好地服务长三角在内的全国客户，公司依托当地优质的人才、区位和产业集聚等优 势，在南京设立了蛋白研发中心和自主品牌研发生产运营基地，在杭州设有抗体研发中心。通过持续的 资源投入和业务深耕，长三角地区已成为公司最重要的业务区域之一。公司将会继续深耕以上海为中心 的长三角地区，持续挖掘客户需求，为包括长三角区域在内的所有客户提供更加优质的产品和服务。 ...

Group 1: Financial Performance - The overall gross margin for the company's proprietary brands is approximately 50% [1] - Revenue from proprietary brands is expected to grow nearly 30% year-on-year by 2024, indicating a strong growth trend [1] - The current revenue share from proprietary brands is relatively low, but is anticipated to increase with enhanced sales resource investment and product pipeline expansion [1] Group 2: Research and Development - The company is focusing its R&D investments primarily in the fields of antibodies and proteins [1] - As of the end of 2024, the Hangzhou antibody R&D center has developed over 2,900 SPUs (Standard Product Units) including paired antibodies and diagnostic antibodies [1] - The Nanjing protein R&D center has developed over 1,700 SPUs, including drug targets and cytokines, and has introduced new products like one-step Elisa kits [1] Group 3: Share Repurchase and Incentive Plans - In 2024, the company initiated a share repurchase plan, utilizing 25,987,076 CNY to buy back 927,600 shares, intended for equity incentives or employee stock ownership plans [1] - A new share repurchase plan is set to use between 15 million and 30 million CNY of its own funds for share buybacks aimed at capital reduction [1][2] - Future equity incentive plans will be introduced based on business development needs to enhance motivational effects [2] Group 4: Mergers and Acquisitions Strategy - The company aims to strengthen channel and R&D capabilities to better serve customers and provide diverse product offerings [2] - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [2]

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the **Chinese research service market**, particularly focusing on the **biotechnology sector** and the challenges faced in the **domestic and foreign markets** [1][5][7]. Core Insights and Arguments - **High Domestic Replacement Rates**: The domestic market has a high localization rate for general and high-purity reagents, such as HQC reagents. However, high-end mass spectrometry and ultra-pure reagents still face significant technical barriers for domestic replacement [1][2][4]. - **Impact of US-China Relations**: The US-China trade relations and tariffs have affected the ability of Chinese research service companies to expand internationally. There is a growing desire for self-sufficiency, but the short-term increase in domestic replacement rates is not significant [5][6]. - **Foreign Investment in China**: Foreign companies like Thermo Fisher and Merck are increasing their investments in local production lines in China to mitigate the impact of tariffs. This includes establishing factories in Wuxi and Nantong [1][6]. - **Market Growth Projections**: The overall growth rate for biotechnology companies is expected to be low in 2025 due to tariffs, increased domestic inventory, and the impact of domestic replacement [3][13]. - **Customer Behavior**: Customers are increasingly concerned about supply chain stability, leading to panic buying and stockpiling of products [5][15]. Additional Important Content - **Product Categories**: The research service sector is divided into biological design and chemical design, with significant growth in areas like LVD and CRO due to the pandemic [2]. - **Barriers to Entry**: High-end products in the mass spectrometry and ultra-pure reagent categories have high barriers to entry, with customers requiring strong quality and technical reputation [4][8]. - **Price Trends**: Prices for certain reagents are declining due to increased competition and inventory pressures, with some imported reagents seeing price reductions of 5% to 10% [15][16]. - **Future Strategies for Companies**: Companies are advised to either focus on a large market segment to achieve monopolistic status or pursue acquisitions to create a comprehensive product line [20]. - **Market Dynamics**: The market is experiencing a potential shakeout, with smaller manufacturers facing intense competition, which may lead to consolidation through mergers and acquisitions [21][23]. Conclusion - The Chinese research service market is navigating complex challenges due to international relations, domestic competition, and evolving customer needs. While there are opportunities for growth, particularly in domestic production, the overall outlook remains cautious with significant barriers to entry in high-end product categories.

Financial Performance - In Q1 2025, the company achieved revenue of 606 million yuan, representing a year-on-year growth of 20.05% [1] - The net profit attributable to shareholders reached 62.38 million yuan, with a significant year-on-year increase of 272.28% [1] - The gross profit margin stood at 48.58%, an increase of 7.78 percentage points compared to the previous year [1] - As of the end of Q1, the company's total assets rose to 5.714 billion yuan [1] Industry Context - The global trade environment is undergoing profound changes, particularly due to escalating tensions in US-China trade relations [2] - The anticipated price increases for certain research service products from the US are expected to enhance the price competitiveness of domestic brands in China [2] - The domestic market is likely to see an acceleration in the process of domestic substitution, particularly in high-frequency repurchase products like research reagents [2] Business Development - The company has established a strong presence in the life sciences reagent sector, having developed over 37,000 products and accumulated more than 141,000 types of life science reagents [3] - The company operates eight business centers globally, serving over 13,000 clients, which solidifies its leading market position [3] - The front-end life sciences reagent business has shown robust growth, with its revenue share significantly increasing compared to the previous year [3] Innovation and Collaboration - The company is actively exploring the application of AI technology in new drug development, aiming to create an "AI + biomedicine" innovation hub [4] - A partnership with East China Normal University has been established to develop an "AI Drug Discovery Joint Laboratory," focusing on ADC drug database construction and AI-driven drug manufacturing [4] Backend Business and Global Strategy - The backend business is focused on specialty generic drug APIs and related intermediates, with a strong emphasis on meeting the growing demand for GMP commercial production capacity [5] - The company has launched a new ADC CDMO base in Chongqing, which provides comprehensive services from toxin synthesis to antibody conjugation and formulation [5] - The backlog of orders in the backend business has increased by over 30% year-on-year, indicating strong customer demand [5] Future Outlook - The company plans to deepen the operational efficiency and collaborative development of its three main business engines: tool compounds and biochemical reagents, molecular building blocks, and APIs and intermediates [6] - The focus for 2025 will be on sustainable high-quality development through co-creation and exploring new growth directions [6]

Core Insights - Shanghai Haoyuan Pharmaceutical Co., Ltd. reported a revenue of 606 million yuan for Q1 2025, representing a year-on-year growth of 20.05%, and a net profit attributable to shareholders of 62.38 million yuan, up 272.28% [1] - The total assets of the company reached 5.714 billion yuan by the end of Q1 [1] - The global trade environment is undergoing significant changes, with high-frequency repurchase characteristics of research reagents likely accelerating domestic substitution [1] Business Performance - The front-end life science reagent business of the company showed strong growth, with its revenue share significantly increasing compared to the same period last year [2] - The backlog of orders in the back-end business increased by over 30% year-on-year, indicating a notable rise in customer demand [2] Innovation and R&D - The company is actively exploring the application of AI technology in new drug development, aiming to establish an "AI + Biomedicine" innovation hub [2] - A partnership has been formed with East China Normal University to create an "AI Drug Exploration Joint Laboratory," focusing on ADC drug database construction and AI drug intelligent manufacturing [2] - The initiative aims to enhance the company's technological barriers in the entire drug development process and accelerate the transition of research results from the laboratory to production [2]